GDTC Company Profile and Key Details

CytoMed Therapeutics Limited generated EPS of -$0.24 over the past year. Five-year average earnings growth is -290.76%.

GDTC has shown weak momentum, losing -15.32% over the past week and -54.15% over the past quarter, though year-to-date performance is down -21.35%. Short-term trend indicators are bullishly aligned (SMA20 9.06%, SMA50 -20.78%, SMA200 -43.54%). The stock’s 14-day RSI is 49.46 (neutral), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -70.65% below its high and over 48.31% above its low. Average 10-day trading volume of 3.10 million shares is significantly above the 3-month average of 516.00 thousand, indicating heightened recent market interest.

CytoMed Therapeutics Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.23. This means the shares are trading above this model’s fair value.

CytoMed Therapeutics Limited has 11.54 million shares outstanding. The public float is 3.59 million shares, elevated short interest at 1.19% of float. This equals 38.92 thousand shares. The short ratio is 2.31 days. Institutional investors hold 0.14% of the float. Insiders own 69.27%.

CytoMed Therapeutics Limited (NASDAQ:GDTC) closed at $1.08 USD, gaining $0.23 (27.07%) from the previous close of $0.85. The stock is currently mid-range between its 52-week high and low $0.73 and $3.68. With a market capitalization of about $12.67 million, CytoMed Therapeutics Limited is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.12). Key stats such as the average daily volume over the past year has been around 206.00 thousand shares, trading with heavier-than-usual volume. Headquartered in Singapore, None, CytoMed Therapeutics Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Chee Kong Choo, the company employs approximately 43 people and listed since April 14, 2023. CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers.

CytoMed Therapeutics Limited trades at a P/E ratio of -4.23, slightly below the S&P 500 average, with a price-to-sales ratio of 38.39 and a price-to-book ratio of 2.52 suggesting the stock is closer to book value. The P/FCF stands at -4.64, also above market averages.

CytoMed Therapeutics Limited (NASDAQ:GDTC) shares are down -21.35% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows CytoMed Therapeutics Limited trading at a premium to the broader market with a P/E of -4.23. Analyst sentiment is cautious, with the majority of ratings in Speculative Buy territory and a mean price target of $5.00, suggesting 362.96% upside. Our AI forecast model points to short-term weakness (-47.22% over two weeks), a medium-term fall (-73.15% over three months), and a longer-term loss (-73.15% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that CytoMed Therapeutics Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -47.22%, with price expected at $0.57 by February 18, 2026, within a range of $0.48 to $0.67 3-Month Outlook: Projected fall of -73.15%, reaching $0.29 by May 05, 2026, with a range of $0.22 to $0.36. 1-Year Outlook: Projected loss of -73.15%, with price at $0.29 by February 04, 2027, within a range of $0.00 to $0.00.